Wei-Han Huang, Associate Director

Doctor Code：25030

Current position

Lecturer of Department of Medicine, Tzu Chi University (Aug. 2017 ~ till now)
Director & Attending physician, Department of Clinical Pathology and Laboratory Medicine, Hualien Tzu Chi Hospital (Jul. 2013~ till now)
Attending physician, Division of Hematology & Oncology, Department of Internal Medicine, Hualien Tzu Chi Hospital (Jul. 2013 ~ till now)
Associate Director, Immunology-Oncology Division, Center of Stem Cell & Precision Medicine (Feb 2019 ~ till now)
Secretary General of Taiwan Society of Clinical Pathology & Laboratory medicine (Dec 2018~till now)
Deputy Secretary General of Taiwan Society of Blood Transfusion (Mar 2019~till now)
Members of Clinical Trial Committee of Hematology Society of Taiwan (Aug. 2017 ~ till now)
Medical advisor, Hualien Blood Donation Center (Nov. 2017 ~ till now)

Education and Training

Tzu Chi University, Department of medicine, Doctor of Medicine (Sep. 1997 ~ Jun. 2004)
Medical License No: 036912
Resident of Internal Medicine, Hualien Tzu Chi Hospital (Aug. 2004 ~ Jul. 2007)
Resident of Clinical Pathology, National Taiwan University Hospital (Aug. 2007~ Jun. 2010)
Master training, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University (Sep. 2009 ~ Jun. 2011)
Chief Resident of Internal Medicine, Hualien Tzu Chi Hospital ((Jul. 2010~ Jun. 2011)
Clinical Fellow, Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital (Jul. 2011~Jun. 2013)

Experience

Vice Chief, Center of Quality Management, Hualien Tzu Chi Hospital (Aug. 2017 ~ Jul 2018)
Member of Council, Taiwan Society of Molecular Medicine (Jul. 2015 ~ Dec 2017)

Clinical Trial ongoing

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry – Principal Investigator
A Phase 3, Randomized, Open-label, Active-controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor Naïve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) – Principal Investigator
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia – Co-Investigator
An International, Phase 3, Open-label, Randomized Study of BGB3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma – Principal Investigator
B-MIND : A Phase 2/3, Randomised, Multicentre Study of MOR208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) - Co-Investigator
Phase 1B, Open-Label Study of Safety and Clinical Activity of combining Bendamustine, L-asparaginase, and Dexamethasone (BLADE) in T-cell or NK-cell Lymphomas - Co-Investigator

Research Project

Integrative Research project in Tzu Chi University and Hualien Tzu Chi Hospital
1. (TCMMP106-03-03) Study on the pathological role of IL-10 in multiple myeloma – Principal Investigator

Publications

Thalidomide treatment in a myelofibrosis patient with leukemic transformation.Huang WH, Li MS,ChuSC, Wang TF, Kao RH, Wu YF. International Journal of Hematology, [In press] DOI:10.1007/s12185-013-1478-6
Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae:MIC Matters. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. ClinInfect Dis. 2013 Feb;56(4):488-95
Carbapenem therapy for bacteremia due to extended- spectrum-beta-lactamase- producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Antimicrob Agents Chemother. 2012 Jun;56(6):2888-93.
Clinical characteristics of urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community. Lee JC, Lee NY, Lee HC, Huang WH, Tsui KC,Chang CM, Lee CC, Chen PL, Wu CJ, Hsueh PR, Ko WC. J MicrobiolImmunol Infect. 2012 Apr;45(2):127-33.
Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extendedspectrum_-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Wang SS, Lee NY, Hsueh PR, Huang WH, Tsui KC, Lee HC, Wu CJ, Chang CM, Huang CC, Ko WC. J MicrobiolImmunol Infect. 2011Aug;44(4):282-8.
Carbapenem therapy for bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiellapneumoniae. Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC. DiagnMicrobiol Infect Dis. 2011 May;70(1):150-3.
Non-carriers of reduced-function CYP2C19 alleles are most susceptible to the impairment of the antiplatelet effect of clopidogrel by concomitant use of proton-pump inhibitor. Lee JK, Huang WH, Chiang FT. Eur Heart J. 2010 Sep;31(supp1):619.

Reference book

Atlas of Clinical Microscopy，Second Edition, Oct-2011; Yu Chu-Su, Jen-Kuang Lee, Wei-Han Huang; ISBN-13: 978-957-41-8579-5